[1]卢冲 李新宇 孙宇 刘丽 魏亚芬.胰高血糖素样肽1(GLP-1)改善阿尔茨海默病大鼠模型的认知功能及其机制研究[J].卒中与神经疾病杂志,2019,26(02):193-197.[doi:10.3969/j.issn.1007-0478.2019.02.015]
　Lu Chong*,Li Xinyu,Sun Yu,et al.The effect and mechanism of Glucagon like peptide 1(GLP-1)in improving cognitive function of Alzheimer's disease rat model[J].Stroke and Nervous Diseases,2019,26(02):193-197.[doi:10.3969/j.issn.1007-0478.2019.02.015]
点击复制

胰高血糖素样肽1(GLP-1)改善阿尔茨海默病大鼠模型的认知功能及其机制研究()
分享到：

《卒中与神经疾病》杂志[ISSN:1007-0478/CN:42-1402/R]

卷:
第26卷
期数:
2019年02期
页码:
193-197
栏目:
论 著
出版日期:
2019-04-20

文章信息/Info

Title:
The effect and mechanism of Glucagon like peptide 1(GLP-1)in improving cognitive function of Alzheimer's disease rat model
文章编号:
1007-0478(2019)02-0193-05
作者:
卢冲 李新宇 孙宇 刘丽 魏亚芬
150036 哈尔滨,黑龙江省医院神经内科[卢冲 刘丽 魏亚芬(通信作者)],普外科(孙宇); 哈尔滨医科大学附属第一医院内分泌科[李新宇(并列第一作者)]
Author(s):
Lu Chong*; Li Xinyu; Sun Yu; et al.*
Department of Neurology,Heilongjiang Provincial Hospital,Harbin 150036
关键词:
阿尔茨海默病 胰高血糖素样肽1 PPARγ 淀粉样β蛋白
Keywords:
Alzheimer's disease Glucagon like peptide 1 PPARγ Amyloid beta
分类号:
R742
DOI:
10.3969/j.issn.1007-0478.2019.02.015
文献标志码:
A
摘要:
目的 探讨胰高血糖素样肽1(GLP-1)改善阿尔茨海默病大鼠认知功能的机制。方法 以正常成年雄性SD大鼠为研究对象,将其随机分为正常对照组、AD模型组、AD模型+GLP-1干预组和AD模型+PPARγ抑制剂+GLP-1干预组; 其中AD模型组以侧脑室注射STZ(3 mg/kg,10 μL)制造AD模型,AD模型+GLP-1干预组在AD造模基础上每日腹腔注射利拉鲁肽(200 μg/kg,10 μL),连续给药28 d,AD模型+PPARγ抑制剂+GLP-1干预组在AD造模基础上侧脑室注射PPARγ抑制剂GW9662(2.5 nmol/g,10 μL),随后腹腔注射利拉鲁肽(200 μg/kg,10 μL)并连续给药28 d; 观察4组大鼠在Morris水迷宫中的学习和记忆能力变化; ELISA方法观察各组大鼠海马Aβ42的水平; Western blot观察各组大鼠海马PPARγ蛋白表达水平。结果 与AD模型组比较,GLP-1干预后的AD大鼠在Morris水迷宫中学习和记忆能力明显改善,海马Aβ42的水平显著降低,海马PPARγ蛋白表达水平显著升高(P<0.05); 与AD模型+GLP-1干预组比较,AD模型+PPARγ抑制剂+GLP-1干预组大鼠海马PPARγ蛋白表达水平显著降低,在Morris水迷宫中学习和记忆能力明显下降,海马Aβ42的水平显著增高(P<0.05)。结论 GLP-1可能通过激活PPARγ抑制Aβ 蓄积,从而起到改善阿尔茨海默病的认知功能作用。
Abstract:
ObjectiveTo explore the mechanism of glucagon like peptide 1(GLP-1)in improving cognitive function of Alzheimer's disease rat model.Methods The health adult male SD rats were randomly divided into four groups,which were normal control group,AD model group,AD model+GLP-1 group,and AD model+PPARγinhibitor+GLP-1 group.The AD model rats were made by injection of STZ(3 mg/kg,10 μL)in the lateral ventricle.The rats of AD model+GLP-1 group were made by intraperitoneal injected Liraglutide(200 μg/kg,10 μL)on the basis of AD model for 28 days.The rats of AD model+PPARγinhibitor+GLP-1 group were made by injected PPARγ inhibitor GW9662(2.5 nmol/g,10 μL)into the lateral ventricle on the basis of AD model and then intraperitoneal injected Liraglutide(200 μg/kg,10 μL)for 28 days.The learning and memory ability of each group in the Morris water maze were observed.The level of Aβ42 in the hippocampus of each group was observed by ELISA.And the PPARγ protein expression level in the hippocampus of each group was observed by Western blot.Results Compared with the AD model group,the learning and memory ability of AD rats was significantly improved,and the level of Aβ42 in the hippocampus decreased significantly,and the expression level of PPARγ protein in the hippocampus was significantly increased in AD model+GLP-1 group.Compared with the AD model+GLP-1 group,the expression level of PPARγ protein in the hippocampus was significantly decreased,and the learning and memory ability decreased significantly,and the level of Aβ42 in the hippocampus increased significantly in the AD model+PPARγ inhibitor+GLP-1 group.Conclusion GLP-1 might inhibit the accumulation of Aβ by activating PPARγ,and improve the cognitive function of Alzheimer's disease.

参考文献/References:

[1] Alzheimer's Association.Alzheimer's disease facts and figures [J].Alzheimers Dement,2012,8(2):131-168.
[2] Hardy J,Selkoe DJ.The amyloid hypothesis of Alzheimer's disease:progress and problems on the road to therapeutics[J].Science(New York,N.Y.),2002,297(5580):353-356.
[3] Goedert M.Tau protein and the neurofibrillary pathology ofAlzheimer's disease[J].Trends in Neurosciences,1993,16(11):460-465.
[4] Bloom GS.Amyloid-beta and Tau The Trigger and Bullet in Alzheimer Disease Pathogenesis[J].JAMA Neurology,2014,71(4):505-508.
[5] Li Chao-yun,Zug C,Qu Hong-chun,et al.Hesperidin ameliorates behavioral impairments and neuropathology of transgenic APP/PS1 mice[J].Behavioural Brain Research,2015,281:32-42.
[6] Fei M,Yan Ping-z,Ru Juan-m,et al.Riskfactors for dementia with type 2 diabetesmellitus among elderly People in China[J].Age and Ageing,2013,42(3):398-400.
[7] Dar TA,Sheikh IA,Ganie SA,et al.Molecular linkages between diabetes and alzheimer's disease:current scenario and future prospects[J].CNS & Neurological Disorders-Drug Targets,2014,13(2):290-298.
[8] Janson J,Laedtke T,Parisi JE,et al.Increased risk of type 2 diabetes in Alzheimer disease[J].Diabetes,2004,53(2):474-481.
[9] Kroner Z.The relationship between Alzheimer's disease and diabetes:Type 3 diabetes?[J].Alternative Medicine Review,2009,14(4):373-379.
[10] Duarte AI,Candeias E,Correia SC,et al.Crosstalk between diabetes and brain:glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration[J].Biochimica et Biophysica acta,2013,1832(4):527-541.
[11] Ma Tao,Du Xu-eliang,Pick JE,et al.Glucagon-Like peptide-1 cleavage product GLP-1(9-36)amide rescues synaptic plasticity and memory deficits in alzheimer's disease model mice[J].Journal of Neuroscience,2012,32(40):13701-13708.
[12] McClean PL,Hölscher C.Liraglutide can reverse memory impairment,synaptic loss and reduce plaque load in aged APP/PS1 mice,a model of Alzheimer's disease [J].Neuropharmacology,2014,76( Pt A):57-67.
[13] Monsalve Fa,Pyarasani Rd,Delgado-Lopez F,et al.Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases[J].Mediators of Inflammation,2013,2013:549627.
[14] Sakurai T.Targets of the peroxisome proliferator-activated receptor γ agonist trials for the prevention of Alzheimer disease[J].Archives of Neurology,2011,68(4):542-543.
[15] Heneka MT,Sastre M,Dumitrescu-Ozimek L,et al.Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice[J].Brain,2005,128(Pt 6):1442-1453.
[16] Onuma H,Inukai K,Kitahara A,et al.The glucagon-like peptide 1 receptor agonist enhances intrinsic peroxisome proliferator-activated receptor γ activity in endothelial cells[J].Biochemical and Biophysical Research Communications,2014,451(2):339-344.
[17] Logroscino G,Kang J H,Grodstein F.Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years[J].BMJ(Clinical Research ed.),2004,328(7439):548.
[18] Liu F,Wang Y,Yan M,et al.Glimepiride attenuates Aβ production via suppressing BACE1 activity in cortical neurons [J].NeurosciLett,2013,557( Pt B):90-94.

备注/Memo

备注/Memo:
基金项目:黑龙江省青年科学基金资助项目(QC2015123); 黑龙江省自然科学基金(重点项目)(ZD2015018); 哈尔滨医科大学创新科学研究资助项目(2016LCZX46) (2018-07-17收稿)
更新日期/Last Update: 2019-04-20